Quarterly report pursuant to Section 13 or 15(d)

Loss Per Share (Tables)

v3.20.2
Loss Per Share (Tables)
6 Months Ended
Jun. 30, 2020
Earnings Per Share [Abstract]  
Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share

The following table sets forth the computation of earnings (loss) per share attributable to PAVmed Inc. and loss per share attributable to PAVmed Inc. common stockholders for the respective periods indicated:

 

    Three Months Ended     Six Months Ended  
    June 30,     June 30,  
    2020     2019     2020     2019  
Numerator                        
Net loss - before noncontrolling interest   $ (5,844 )   $ (3,739 )   $ (20,755 )   $ (7,443 )
Net loss attributable to noncontrolling interest     266       145       702       314  
Net loss - as reported, attributable to PAVmed Inc.   $ (5,578 )   $ (3,594 )   $ (20,053 )   $ (7,129 )
                                 
Series B Convertible Preferred Stock dividends:   $ (71 )   $ (66 )   $ (141 )   $ (132 )
                                 
Net loss attributable to PAVmed Inc. common stockholders   $ (5,649 )   $ (3,660 )   $ (20,194 )   $ (7,261 )
                                 
Denominator                                
Weighted average common shares outstanding, basic and diluted     44,781       27,606       44,140       27,344  
                                 
Loss per share                                
Basic and diluted                                
Net loss - as reported, attributable to PAVmed Inc.   $ (0.12 )   $ (0.13 )   $ (0.45 )   $ (0.26 )
Net loss attributable to PAVmed Inc. common stockholders   $ (0.13 )   $ (0.13 )   $ (0.46 )   $ (0.27 )
Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share

The following common stock equivalents have been excluded from the computation of diluted weighted average shares outstanding as their inclusion would be anti-dilutive:

 

    June 30,  
    2020     2019  
PAVmed Inc. 2014 Equity Plan stock options and restricted stock awards     7,965       5,804  
Unit purchase options - as to shares of common stock     53       53  
Unit purchase options - as to shares underlying Series Z Warrants     53       53  
Series Z Warrants     16,815       16,815  
Series W Warrants     382       382  
Series B Convertible Preferred Stock     1,180       1,113  
Total     26,448       24,220